| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Gammagard Liquid vs Hizentra

Side-by-side clinical, coverage, and cost comparison for polyradiculoneuropathy, chronic inflammatory demyelinating.

Deep comparison between: Gammagard Liquid vs Hizentra with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHizentra has a higher rate of injection site reactions vs Gammagard Liquid based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Hizentra but not Gammagard Liquid, including UnitedHealthcare

Category

Gammagard Liquid

Hizentra

At A Glance

RouteIV infusion or SC injection

FrequencyEvery 3-4 weeks (IV) or weekly (SC)

ClassImmune globulin replacement

RouteSC injection

FrequencyDaily to every 2 weeks

ClassImmune globulin

Indications

Common Variable Immunodeficiency
X-linked agammaglobulinemia
Congenital agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency
Multifocal motor neuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Primary immune deficiency disorder
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Wiskott-Aldrich Syndrome
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Severe Combined Immunodeficiency

Dosing

Primary Immunodeficiency (IV) 300-600 mg/kg every 3-4 weeks by IV infusion; start at 0.5 mL/kg/hr, increase every 30 minutes if tolerated up to 5 mL/kg/hr.

Primary Immunodeficiency (SC) Initial dose 1.37 x previous IV dose divided by weeks between IV doses, given weekly; 20-30 mL/site at 20-30 mL/hr/site (>=40 kg) or 20 mL/site at 15-20 mL/hr/site (<40 kg).

Multifocal Motor Neuropathy 0.5-2.4 g/kg/month by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.

Chronic Inflammatory Demyelinating Polyneuropathy Induction 2 g/kg divided over 2-5 consecutive days, then maintenance 1 g/kg divided over 1-4 consecutive days every 3 weeks by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.

Primary immune deficiency disorder, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency Individualized SC dose administered daily to every 2 weeks; when switching from IGIV, initial weekly dose = prior IGIV dose (g) divided by weeks between doses, multiplied by 1.37.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 0.2 g/kg (1 mL/kg) SC per week in 1-2 infusion sessions over 1-2 consecutive days; may increase to 0.4 g/kg per week if symptoms worsen on the lower dose.

Contraindications

Anaphylactic or severe systemic hypersensitivity to human immune globulin
IgA deficiency with antibodies to IgA and history of hypersensitivity

History of anaphylactic or severe systemic reaction to human immune globulin or inactive ingredients of HIZENTRA, including polysorbate 80
Hyperprolinemia Type I or II (HIZENTRA contains L-proline as stabilizer)
IgA-deficiency with antibodies against IgA and a history of hypersensitivity

Drug Interactions

163View drug interactions

Adverse Reactions

Most common (>=5%) - Primary Immunodeficiency (IV) Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, edema peripheral, pruritus, cardiac murmur

Most common (>=5%) - Primary Immunodeficiency (SC) Infusion site events, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, pain in extremity

Most common (>=5%) - Multifocal Motor Neuropathy Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, pain in extremity

Most common (>=5%) - Chronic Inflammatory Demyelinating Polyneuropathy Headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, pain in extremity

Serious Aseptic meningitis (IV for PI), pulmonary embolism, blurred vision (MMN)

Postmarketing Hemolysis, anaphylactic shock, cerebrovascular accident, transient ischemic attack, tremor, myocardial infarction, deep vein thrombosis, hypotension, pulmonary embolism, pulmonary edema, hyperhidrosis, chest pain, transfusion-related acute lung injury, hypersensitivity, myalgia, chills

Most common (>=5%) Local infusion-site reactions (swelling, redness, heat, pain, hematoma, itching), headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain, migraine, arthralgia, pain, fall, nasopharyngitis

Postmarketing Allergic-anaphylactic reactions (swollen face or tongue, pharyngeal edema, pyrexia, chills, dizziness, hypertension, malaise, tachycardia, flushing), chest discomfort, dyspnea, tremor, burning sensation, infusion site ulcer, infusion site necrosis

Pharmacology

GAMMAGARD LIQUID supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents and contains antibodies that interact with immune system cells; the mechanism in CIDP may include immunomodulatory effects.

Immune Globulin Subcutaneous (Human), 20% Liquid that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; mechanism of action has not been fully elucidated but may include immunomodulatory effects.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Gammagard Liquid